폐경여성에서 접합에스트로겐 투여후 혈청지질 및 지질단백치의 변동에 대한 연구

Abstract

폐경여성은 혈청난포호르몬치의 감소로 내분비장애를 일으켜서 이로 인한 대사변화를 유발한다. 폐경 후 안면홍조, 비뇨생식기 위축. 골다공증, 심장혈관질환 빈도의 증가등을 일으키는데 이러한 증상들은 난포호르몬 대치요법으로 효과적으로 치료된다. 또한 폐경여성에서 난포호르몬 대치요법은 혈청지질 및 지질단백에 변화를 유발한다. 이에 본 연구는 폐경 여성 24례를 대상으로 용량이 다른 접합난포호르몬을 경구투여하여 용량에 따른 혈청 Estradiol, FSH, 지질 및 지질 단백의 변화를 비교분석하여 다음과 같은 결론을 얻었다. 1. 접합 난포호르몬 0.625㎎치료군 (Group Ⅰ)과 1.25㎎ 치료군(Group Ⅱ)의 치료 후 혈청 Estradiol치의 변동은 각각 53.95±13.91pg/㎖ (p<0.01), 71.48±20.8 pg/㎖ (p<0.01)로 치료 전보다 증가하였으나, 두 치료군간의 치료후 변동간의 유의한 차이는 없었다(p>0.05). 2. 난포호르몬 치료후 혈청 FSH의 변동은 치료군Ⅰ, Ⅱ에서 각각 50.07±15,79mIu/㎖(p<0.05), 58.98±9.34mIu/㎖(p<0.05)로 치료전보다 감소하였으나 두 치료군간의 치료후 변동간에는 유의한 차이가 없었다 (p>0.05). 3. 난포호르몬 치료후 혈청 Cholesterol치의 변동은 치료군Ⅰ에서 18.75±4.92 ㎎/㎗(p<0.01), 치료군Ⅱ에서 4.75±10.24 ㎎/㎗(P<0.05)로 치료전보다 감소하였고 두 치료군간의 치료후 변동간에는 유의한 차이가 없었다(p>0.05). 4. 난포호르몬 치료후 혈청 triglyceride치의 변동은 치료군Ⅰ에서 46.83±24.62㎎/㎗(p>0.05), 치료군Ⅱ에서 33.42±17.19 ㎎/㎗(P>0.05)로 치료전보다 감소하였으며 두 치료군간의 치료후 변동간의 유의한 차이가 없었다(p>0.05 ). 5. 난포호르몬 치료후 HDL의 변동은 치료군Ⅰ에서 4.92±3.40 ㎎/㎗(p>0.05), 치료군Ⅱ에서 9.67±6.41 ㎎/㎗(p>0.05)로 치료전보다 증가하였고, 두 치료군간의 치료후 변동간에는 유의한 차이가 있었다(p<0.05). 6 .난포호르몬 치료후 혈청 HDL과 cholesterol비는 치료군Ⅰ에서 6.01±1.64%(p<0.01), 치 료군Ⅱ에서 6.33±2.53%(p<0.05)로 치료전보다 증가하였으나 두 치료군간의 치료후 변동간에는 유의한 차이는 없었다(p>0.05). 7. 난포호르몬 치료후 혈청 LDL과 cholesterol의 비는 치료군Ⅰ에서 6.73±2.23%(p<0.01), 치료군Ⅱ에서 10.33±1.62%(p<0.01)로 치료전보다 감소하였고, 두 치료군간의 치료후 변동간에는 유의한 차이는 없었다(p>0.05). 8. 난포호르몬 치료후 혈청 VLDL과 cholesterol비는 치료군Ⅰ, Ⅱ 두에서 치료전에 비하여 유의하지 않은 변동(p>0.05)을 보였으며 두 치료군간의 치료후 변동간에는 유의한 차이가 없었다(p>0.05). 9. 난포호르몬 치료후 혈청 HDL과 LDL의 비는 치료군Ⅰ에서 0,1829±0.0449(p<0.01), 치료군Ⅱ에서 0.2902±0.0624(p<0.01)로 치료전에 비하여 증가하였고 두 치료군의 치료후 변동간에는 유의한 차이가 없었다.;Menopause is endocrinopathy of hypoestrogenic state in women, and metabolic changes result from this ednocrinopathy. Postmenopausal women suffered from hot flush, urogenital atrophy, osteoporosis, increased risk of cardiovascular disease and estrogen replacement therapy may actually improved overall. Postmenopausal estrogen replacement therapy have displayed changes in plasma lipid and lipoprotein level. We administered different doses of oral conjugate estrogen to 24 postmenopausal women and made comparative analysis of lipid and lipoprotein changes according to doses. The results were follows: 1. The changes of plasma estradiol after estrogen replacement therapy in Group Ⅰ and Group Ⅱ were increased by 53.95±13.91 pg/ml (P < 0.01) and 71.48±20.80 pg/ml (P<0.01), but difference of changes between two groups was not statistically significant (P > 0.05). 2. The changes of plasma FSH after estrogen replacement therapy in Group Ⅰ and Group Ⅱ were decreased by 50.07±15.79mIU/ml(P < 0.05), and 58.95±9.34 mIU/ml(P < 0.01), but difference of changes between two groups was not statistically significant (P > 0.05). 3. The changes of plasma cholesterol after estrogen replacement therapy in Group Ⅰ and Group Ⅱ were decreased 18.75±4.92mg/dl(P < 0.01) and 4.75±10.24(P >0.05), but difference of changes between two Groups was not statistically significant (P > 0.05). 4. The changes of plasma triglyceride after estrogen replacement therapy in Group Ⅰ and Group Ⅱ were decreased by 46.83+24.62 mg/dl(P > 0.05) and 33.43±17.19 mg/dl(P > 0.05), but difference of changes between two Groups was not statistically : significant (P > 0.05). 5. The changes of plasma HDL after estrogen replacement therapy in Group Ⅰ and Group Ⅱ were increased by 4.92±3.40 mg/dl(P > 0.05) and 9.67±6.41 mg/dl(P >0.05), but difference of changes between two Groups was statistically significant(P < 0.05) 6. The change of plasma HDL/Cholesterol after estrogen replacement therapy in Group Ⅰ and Group Ⅱ were increased by 6.01±1.64%(P < 0.01) and 6.33±2.53%(P < 0.05), but difference of changes between two Groups was not statistically significant (P > 0.05). 7. The changes of plasma LDL/Cholesterol after estrogen replacement therapy Group Ⅰ and Group Ⅱ were decreased by 6.73+2.23%(P < 0.01) and 10.33±1.62%(P < 0.01), but difference of changes between two Groups was not statistically significant (P > 0.05). 8. The changes of plasma VLDL/Cholesterol after estrogen replacement therapy Group Ⅰ and Group Ⅱ were increased by 1.70±3.07%(P > 0.05) and 5.06±2.6I%(P > 0.05), but difference of changes between two Groups was not statistically significant (P > 0.05). 9. The changes of plasma HDL/LDL after estrogen replacement therapy in Group Ⅰ and Group Ⅱ were increased by 0.1829±0.0449%(P < 0.01) and 0.2902±0.0624%(P < 0.01), but difference of changes between two Groups was not statistically significant (P > 0.05).